Tenax Therapeutics, Inc. financial data

Symbol
TENX on Nasdaq
Industry
Pharmaceutical Preparations
Location
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC
State of incorporation
DE
Fiscal year end
December 31
Former names
OXYGEN BIOTHERAPEUTICS, INC. (to 9/15/2014), SYNTHETIC BLOOD INTERNATIONAL INC (to 6/30/2008)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.38K % +32%
Debt-to-equity 7.83 % -27.1%
Return On Equity 15.3 % -88.3%
Return On Assets 14.2 % -88%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.41M shares -85.7%
Common Stock, Shares, Outstanding 3.41M shares -85.7%
Entity Public Float 7.03M USD +40.5%
Common Stock, Value, Issued 341 USD -85.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.81M USD +268%
General and Administrative Expense 5.73M USD +19.7%
Operating Income (Loss) 10.8M USD +147%
Net Income (Loss) Attributable to Parent 4.84M USD -63.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.4M USD +85.3%
Other Assets, Current 33.9K USD -87.3%
Assets, Current 99.8M USD +740%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 1.12K USD 0%
Assets 99.8M USD +739%
Accounts Payable, Current 1.58M USD +1075%
Employee-related Liabilities, Current 872K USD +1738%
Accrued Liabilities, Current 978K USD +234%
Liabilities, Current 2.56M USD +325%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 2.56M USD +325%
Retained Earnings (Accumulated Deficit) -309M USD -4.95%
Stockholders' Equity Attributable to Parent 97.2M USD +761%
Liabilities and Equity 99.8M USD +739%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.72M USD +41.3%
Net Cash Provided by (Used in) Financing Activities 7.92M USD -43.5%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 3.41M shares -85.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.72M USD -0.07%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.3M USD +782%
Deferred Tax Assets, Valuation Allowance 38.7M USD +3.08%
Operating Lease, Liability 0 USD -100%
Depreciation 6.57K USD +53.3%
Payments to Acquire Property, Plant, and Equipment 1.24K USD -80.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 11M USD
Lessee, Operating Lease, Liability, to be Paid 228K USD -35.6%
Operating Lease, Liability, Current 116K USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65.7K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 130K USD +2.52%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, to be Paid, Year Three 130K USD +2.52%
Deferred Tax Assets, Operating Loss Carryforwards 36.8M USD +2.02%
Preferred Stock, Shares Issued 210 shares
Preferred Stock, Shares Authorized 4.82M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 65.7K USD -49.4%
Additional Paid in Capital 406M USD +32.9%
Preferred Stock, Shares Outstanding 5.18M shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 25.6K USD +17.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares